. Author manuscript; available in PMC: 2009 Jan 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2007 Mar 29;61(1):133–144. doi: 10.1007/s00280-007-0458-z

Table 3.

Mean concentrations (μg/g of tissue) of rapamycin in rat tissues (and tissue to plasma rations—K_d values—in parenthesis) measured at 24 h post IV administration of control rapamycin, rapamycin in PEG-b-PCL, and rapamycin in PEG-b-PCL + α-tocopherol in plasma after IV administration (mean ± SEM, n = 4)

Tissue	Rapamycin control	Rapamycin in PEG-b-PCL	Rapamycin in PEG-b-PCL + α-tocopherol
Plasma	0.020 ± 0.002	0.015 ± 0.002	0.020 ± 0.001
Blood	0.018 ± 0.004 (0.989 ± 0.011)	0.013 ± 0.001^a (0.739 ± 0.052)^a	0.018 ± 0.002^b (0.828 ± 0.022)^a
Liver	0.663 ± 0.076 (33.659 ± 7.210)	0.534 ± 0.021 (35.143 ± 1.386)	0.528 ± 0.022 (23.865 ± 1.959)^a,^b
Kidney	0.704 ± 0.106 (35.870 ± 8.907)	0.553 ± 0.016 (32.513 ± 2.831)	0.664 ± 0.005 (28.217 ± 1.657)
Spleen	0.668 ± 0.074 41.708 ± 0.687)	0.556 ± 0.018 (32.425 ± 5.362)^a	0.499 ± 0.011^a,^b (22.330 ± 1.529)^a,^b
Brain	0.300 ± 0.067 (18.391 ± 7.889)	0.075 ± 0.005^a (5.172 ± 0.636)^a	0.076 ± 0.004^a (3.357 ± 0.164)^a,^b
Muscle	0.173 ± 0.019 (9.804 ± 1.319)	0.174 ± 0.023 (12.851 ± 0.599)	0.153 ± 0.013 (6.131 ± 0.094)^a,^b
Lung	0.721 ± 0.105 (44.839 ± 0.834)	0.710 ± 0.036 (39.645 ± 3.911)	0.568 ± 0.014^b (25.793 ± 2.919)^a,^b
Heart	0.445 ± 0.034 (27.919 ± 1.430)	0.382 ± 0.004 (22.498 ± 2.409)^a	0.362 ± 0.005 (16.997 ± 1.098)^a,^b
Urinary bladder	0.529 ± 0.019 (30.000 ± 2.942)	0.482 ± 0.027 (31.741 ± 1.782)	0.892 ± 0.080^a,^b (38.562 ± 8.195)

Denotes statistical significant difference (P < 0.05) between control and formulation

Denotes statistical significant difference (P < 0.05) between both formulations